Phone: +43 1 367 13 73
office@drschindl.at
ONLINE-APPOINTMENT
UNIV. PROF. DR. MARTIN SCHINDL

PUBLICATIONS

EXPERT FOR PANCREAS, LIVER, GALLBLADDER AND BILIARY TRACT

SELECTION OF PUBLICATIONS UNIV. PROF. DR. MARTIN SCHINDL

 

  1. Bastati N, Kristic A, Poetter-Lang S, Messner A, Herold A, Hodge JC, Schindl M, Ba-Ssalamah A.
    Imaging of inflammatory disease of the pancreas.
    Br J Radiol. 2021.
     
  2. Kloesch B, Ionasz V, Paliwal S, Hruschka N, Martinez de Villarreal J, Öllinger R, Mueller S, Dienes HP, Schindl M, Gruber ES, Stift J, Herndler-Brandstetter D, Lomberk GA, Seidler B, Saur D, Rad R, Urrutia RA, Real FX, Martinelli P.
    A GATA6-centred gene regulatory network involving HNFs and ?Np63 controls plasticity and immune escape in pancreatic cancer.
    Gut. 2021.
     
  3. Schwarz C, Fitschek F, Primavesi F, Stättner S, Margonis GA, Weiss MA, Stavrou GA, Oldhafer KJ, Kornprat P, Wundsam H, Fischer I, Längle F, Függer R, Hauer A, Klug R, Kieler M, Prager G, Schindl M, Stremitzer S, Bodingbauer M, Sahora K, Kaczirek K.
    Metachronous hepatic resection for liver only pancreatic metastases.
    Surg Oncol. 2020.
     
  4. Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M.
    The prognostic index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection.
    Ann Surg Oncol. 2020.
     
  5. Taghizadeh H, Müllauer L, Mader RM, Schindl M, Prager GW.
    Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.
    Ther Adv Med Oncol. 2020.
     
  6. Kieler M, Unseld M, Bianconi D, Schindl M, Kornek GV, Scheithauer W, Prager GW.
    Impact of new chemotherapy regimens on the treatment landscape and survival of locally advanced and metastatic pancreatic cancer patients.
    J Clin Med. 2020.
     
  7. Beer L, Toepker M, Ba-Ssalamah A, Schestak C, Dutschke A, Schindl M, Wressnegger A, Ringl H, Apfaltrer P.
    Objective and subjective comparison of virtual monoenergetic vs. polychromatic images in patients with pancreatic ductal adenocarcinoma.
    Eur Radiol. 2019.
     
  8. Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, Schindl M.
    Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. J Gastrointest Surg. 2019.
     
  9. Gruber ES, Jomrich G, Tamandl D, Gnant M, Schindl M, Sahora K.
    Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic durctal adenocarcinoma.
    PLoS One. 2019.
     
  10. Stutchfield BM, Bodingbauer MW, Adair A, Wakelin S, Schindl M, Forbes SJ, et al.
    Quantifying changes in innate immune function following liver transplantation for chronic liver disease. HPB (Oxford). 2019.
     
  11. Schindl M, Függer R, Götzinger P, Längle F, Zitt M, Stättner S, et al.
    Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. Br J Surg. 2018.
     
  12. Chamokova B, Bastati N, Poetter-Lang S, Bican Y, Hodge JC, Schindl M, et al.
    The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases. The British Journal of Radiology. 2018.
     
  13. Bolliger M, Kroehnert JA, Molineus F, Kandioler D, Schindl M, Riss P.
    Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients. Eur Surg. 2018.